Amgen Settles Patent Lawsuit Over Biosimilar Version of J&J’s Stelara

Johnson & Johnson has settled its lawsuit over Amgen Inc’s proposed biosimilar version of J&J’s top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court.

Amgen said in a statement on Tuesday that the settlement terms are confidential, but it will allow the company to sell its biosimilar of Stelara “no later than January 1st, 2025.”

A J&J spokesperson said the company will “continue to defend the intellectual property associated with our medicines to protect our ability to innovate and develop life-changing therapies for patients.”

Read the source article at finance.yahoo.com